- Home
- CDTG vs LVTX Comparison
CDTG vs LVTX Comparison
Compare CDTG & LVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTG
- LVTX
- Stock Information
- Founded
- CDTG 2012
- LVTX 2016
- Country
- CDTG China
- LVTX Netherlands
- Employees
- CDTG N/A
- LVTX N/A
- Industry
- CDTG
- LVTX Biotechnology: Pharmaceutical Preparations
- Sector
- CDTG
- LVTX Health Care
- Exchange
- CDTG NYSE
- LVTX Nasdaq
- Market Cap
- CDTG 34.6M
- LVTX 27.9M
- IPO Year
- CDTG 2024
- LVTX 2021
- Fundamental
- Price
- CDTG $1.50
- LVTX $0.96
- Analyst Decision
- CDTG
- LVTX Buy
- Analyst Count
- CDTG 0
- LVTX 3
- Target Price
- CDTG N/A
- LVTX $3.33
- AVG Volume (30 Days)
- CDTG 44.3K
- LVTX 27.7K
- Earning Date
- CDTG 04-03-2025
- LVTX 03-19-2025
- Dividend Yield
- CDTG N/A
- LVTX N/A
- EPS Growth
- CDTG N/A
- LVTX N/A
- EPS
- CDTG 0.72
- LVTX N/A
- Revenue
- CDTG $31,432,824.00
- LVTX $7,345,000.00
- Revenue This Year
- CDTG N/A
- LVTX $16.68
- Revenue Next Year
- CDTG N/A
- LVTX N/A
- P/E Ratio
- CDTG $2.08
- LVTX N/A
- Revenue Growth
- CDTG N/A
- LVTX N/A
- 52 Week Low
- CDTG $1.16
- LVTX $0.85
- 52 Week High
- CDTG $4.64
- LVTX $6.47
- Technical
- Relative Strength Index (RSI)
- CDTG N/A
- LVTX 46.74
- Support Level
- CDTG N/A
- LVTX $0.85
- Resistance Level
- CDTG N/A
- LVTX $0.98
- Average True Range (ATR)
- CDTG 0.00
- LVTX 0.05
- MACD
- CDTG 0.00
- LVTX 0.01
- Stochastic Oscillator
- CDTG 0.00
- LVTX 59.72
About CDTG CDT ENVIRONMENTAL TECH INV HLDG LTD
CDT Environmental Technology Investment Holdings Ltd is a waste treatment company. The company generates revenue through the design, development, manufacture, sales, installation, operation and maintenance of sewage treatment systems and by providing sewage treatment services. It engages in two business lines namely, rural sewage treatment and septic tank treatment in both urban and rural areas.
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.